Oracle Corporation vs Smith & Nephew plc — how do they compare? Oracle Corporation trades at $125.94 (market cap $365.96B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Oracle Corporation is far larger — about 28.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| ORCL | SNN | |
|---|---|---|
Market Cap | $365.96B | $12.71B |
Sector | Technology | Health |
52-Week High | $328.33 | $38.70 |
52-Week Low | $121.37 | $28.73 |
Enterprise Value | $495.21B | $15.48B |
Dividend Yield | 1.57% | 2.59% |
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) trades at $125.86, up 3.7% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 21.67% net margins and consistent revenue growth. Recent AI partnerships and infrastructure investments position Oracle as a key player in the enterprise cloud and AI markets, though high valuation multiples and significant debt levels warrant caution.
Oracle presents a compelling growth story driven by AI infrastructure demand, with analyst consensus strongly bullish (65% buy ratings) and a $253.30 price target representing significant upside. Key risks include high leverage, competitive pressures, and execution challenges in capital-intensive AI expansion. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →